IBI318 is a recombinant bispecific IgG1 antibody that targets PD-1 and PD-L1. Here the authors report the results of a phase II trial of IBI318 combined with the receptor tyrosine kinase inhibitor lenvatinib in patients with advanced non-small cell lung cancer with acquired resistance to first-line immune checkpoint inhibitors.
- Liang Zeng
- Zhaohui Ruan
- Yongchang Zhang
